- Home
- GTLS vs MDGL Comparison
GTLS vs MDGL Comparison
Compare GTLS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTLS
- MDGL
- Stock Information
- Founded
- GTLS 1859
- MDGL 2011
- Country
- GTLS United States
- MDGL United States
- Employees
- GTLS N/A
- MDGL N/A
- Industry
- GTLS Metal Fabrications
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GTLS Industrials
- MDGL Health Care
- Exchange
- GTLS Nasdaq
- MDGL Nasdaq
- Market Cap
- GTLS 7.1B
- MDGL 7.4B
- IPO Year
- GTLS 1992
- MDGL N/A
- Fundamental
- Price
- GTLS $184.69
- MDGL $308.44
- Analyst Decision
- GTLS Strong Buy
- MDGL Buy
- Analyst Count
- GTLS 13
- MDGL 14
- Target Price
- GTLS $187.23
- MDGL $347.33
- AVG Volume (30 Days)
- GTLS 871.8K
- MDGL 355.8K
- Earning Date
- GTLS 11-01-2024
- MDGL 10-31-2024
- Dividend Yield
- GTLS N/A
- MDGL N/A
- EPS Growth
- GTLS N/A
- MDGL N/A
- EPS
- GTLS 3.20
- MDGL N/A
- Revenue
- GTLS $4,068,500,000.00
- MDGL $76,813,000.00
- Revenue This Year
- GTLS $29.16
- MDGL N/A
- Revenue Next Year
- GTLS $10.85
- MDGL $194.49
- P/E Ratio
- GTLS $57.42
- MDGL N/A
- Revenue Growth
- GTLS 46.41
- MDGL N/A
- 52 Week Low
- GTLS $101.60
- MDGL $168.25
- 52 Week High
- GTLS $204.23
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- GTLS 52.31
- MDGL 51.11
- Support Level
- GTLS $187.51
- MDGL $289.80
- Resistance Level
- GTLS $201.10
- MDGL $315.09
- Average True Range (ATR)
- GTLS 8.02
- MDGL 12.44
- MACD
- GTLS -3.22
- MDGL -4.11
- Stochastic Oscillator
- GTLS 31.10
- MDGL 48.58
About GTLS Chart Industries Inc.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.